Home / TELO : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does TELO make money? Does TELO have pricing power? What's the Earnings Whisper? Will TELO profit more as the business scales? What is TELO's management track record? Is TELO's current price justified?

Telomir Pharmaceuticals, Inc. Common Stock

$1.17 -$0.17 (-12.69%)

NASDAQ · 14 Sep 2026 20:00 UTC

Previous Close

$1.17

Day Range

$1.11$1.2

Year Range

$0.89$2.09

Market Cap

80.47M

AVG Volume

91.33K

Trailing/Forward PE

-0.77/-

PEG ratio

0.08

Dividend Yield

Next Earnings Date

2026-12-02

Primary Exchange

NASDAQ

Net Income (USD)

TELO Net Income (USD) by year
Period	Net Income (USD)
2025	-10.41M
2024	-16.59M
2023	-13.07M
2022	-854.15K

Operating Income (USD)

TELO Operating Income (USD) by year
Period	Operating Income (USD)
2025	-10.54M
2024	-12.3M
2023	-3.94M
2022	-854.15K

EBITDA (USD)

TELO EBITDA (USD) by year
Period	EBITDA (USD)
2025	-10.41M
2024	-10.31M
2023	-10.95M
2022	-296.99K

Cash Flows (USD)

TELO Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-3.69M
2024	-5.07M
2023	-3.86M
2022	-468.66K

EPS (USD)

TELO EPS (USD) by year
Period	EPS (USD)
2025	-0.34
2024	-0.58
2023	-0.45
2022	-0.03

Expenses (USD)

TELO Expenses (USD) by year
Period	Expenses (USD)
2025	10.54M
2024	11.93M
2023	2.76M
2022	854.15K

Cash & Debt (USD)

TELO Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	7.29M
2024	1.27M
2023	1.23K
2022	1.42K

Debt ratios

TELO Debt ratios by year
Period	Debt ratios
2025	0.21

Return on Capital

TELO Return on Capital by year
Period	Return on Capital
2025	-176.1%
2024	-2580.37%
2023	-380.19%
2022	91.13%

Shares Outstanding

TELO Shares Outstanding by year
Period	Shares Outstanding
2025	34.38M
2024	29.54M
2023	29.61M
2022	29.61M

Book Value Per Share (USD)

TELO Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	0.17
2024	0.02
2023	0.12
2022	-0.03

Total Assets (USD)

TELO Total Assets (USD) by year
Period	Total Assets (USD)
2025	7.34M
2024	1.32M
2023	4.77M
2022	48.73K

Employee Count

TELO Employee Count by year
Period	Employee Count
2025	2
2024	5
2023	1

Free Cash Flow Yield

TELO Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-12.22%
Sep 26	-12.22%
Sep 26	-12.32%
Aug 26	-12.54%
Aug 26	-12.65%
Aug 26	-13.11%
Aug 26	-11.53%
Jul 26	-11.05%
Jul 26	-11.63%
Jul 26	-12.05%
Jul 26	-10.87%
Jul 26	-10.53%
Jun 26	-10.79%
Jun 26	-9.42%
Jun 26	-10.62%
Jun 26	-11.05%
May 26	-10.29%
May 26	-10.37%
May 26	-10.62%
May 26	-8.25%
May 26	-7.66%
Apr 26	-7.66%
Apr 26	-7.4%
Apr 26	-8.79%
Apr 26	-8.45%
Mar 26	-8.58%
Mar 26	-8.13%
Mar 26	-7.55%
Mar 26	-7.97%
Feb 26	-7.85%
Feb 26	-8.74%
Feb 26	-9.14%
Feb 26	-8.66%
Jan 26	-8.74%
Jan 26	-7.44%
Jan 26	-7.17%
Jan 26	-7.33%
Jan 26	-7.44%
Dec 25	-6.82%
Dec 25	-7.07%
Dec 25	-6.87%
Dec 25	-7.27%
Nov 25	-7.44%
Nov 25	-7.78%
Nov 25	-7.38%
Nov 25	-8.06%
Oct 25	-6.77%
Oct 25	-7.04%
Oct 25	-6.72%
Oct 25	-6.4%
Oct 25	-7.54%
Sep 25	-7.59%
Sep 25	-6.9%
Sep 25	-7.76%
Sep 25	-8.51%
Aug 25	-8%
Aug 25	-7.28%
Aug 25	-7.08%
Aug 25	-8.6%
Aug 25	-7.62%
Jul 25	-6.13%
Jul 25	-5.89%
Jul 25	-11.57%
Jul 25	-11.67%
Jun 25	-8.77%
Jun 25	-7.62%
Jun 25	-6.85%
Jun 25	-6.24%
May 25	-6.88%
May 25	-6.39%
May 25	-5.37%
May 25	-6.89%
May 25	-6.63%
Apr 25	-6.73%
Apr 25	-6.92%
Apr 25	-6.38%
Apr 25	-5.86%
Mar 25	-4.35%
Mar 25	-3.76%
Mar 25	-3.75%
Mar 25	-3.95%
Feb 25	-4.29%
Feb 25	-4.39%
Feb 25	-4%
Feb 25	-3.93%
Jan 25	-3.86%
Jan 25	-3.73%
Jan 25	-4%
Jan 25	-4.56%
Jan 25	-4.15%
Dec 24	-3.85%
Dec 24	-3.62%
Dec 24	-3.61%
Dec 24	-2.88%
Nov 24	-4.71%
Nov 24	-4.42%
Nov 24	-5.03%
Nov 24	-5.24%
Nov 24	-5.21%
Oct 24	-4.98%

Price to Book

TELO Price to Book by year
Period	Price to Book
Sep 26	7.99
Sep 26	7.99
Sep 26	7.92
Aug 26	7.79
Aug 26	7.72
Aug 26	7.45
Aug 26	8.04
Jul 26	8.38
Jul 26	7.97
Jul 26	7.69
Jul 26	8.52
Jul 26	8.8
Jun 26	8.59
Jun 26	9.84
Jun 26	8.73
Jun 26	8.38
May 26	9.01
May 26	8.94
May 26	8.73
May 26	7.56
May 26	8.14
Apr 26	8.14
Apr 26	8.43
Apr 26	7.09
Apr 26	7.38
Mar 26	7.27
Mar 26	7.67
Mar 26	5.87
Mar 26	5.56
Feb 26	5.65
Feb 26	5.07
Feb 26	4.85
Feb 26	5.11
Jan 26	5.07
Jan 26	5.96
Jan 26	6.18
Jan 26	6.05
Jan 26	5.96
Dec 25	6.49
Dec 25	6.27
Dec 25	6.45
Dec 25	6.09
Nov 25	5.96
Nov 25	5.69
Nov 25	6
Nov 25	81.69
Oct 25	97.29
Oct 25	93.54
Oct 25	97.91
Oct 25	102.9
Oct 25	87.31
Sep 25	86.68
Sep 25	95.41
Sep 25	84.81
Sep 25	77.33
Aug 25	82.32
Aug 25	90.43
Aug 25	92.92
May 25	114.38
May 25	118.98
Apr 25	117.14
Apr 25	113.92
Apr 25	123.57
Apr 25	134.6
Mar 25	181.45
Mar 25	209.47
Mar 25	210.39
Mar 25	199.83
Feb 25	183.75
Feb 25	179.61
Feb 25	197.07
Feb 25	200.74
Jan 25	325.52
Jan 25	336.91
Jan 25	314.13
Jan 25	275.28
Jan 25	302.75
Dec 24	326.19
Dec 24	346.95
Dec 24	348.29
Dec 24	436.71
Nov 24	266.58
Nov 24	283.99
Nov 24	249.83
Nov 24	79.71
Nov 24	80.28
Oct 24	83.87
Oct 24	88.78
Oct 24	95.77
Oct 24	102.57
Sep 24	128.82
Sep 24	148.09
Sep 24	114.66
Sep 24	97.28
Aug 24	98.98
Aug 24	99.17
Aug 24	75.37
Aug 24	41.64
Aug 24	32.42
Jul 24	37.66

No video analysis for this stock yet. Request one from our team.

News: TELO

globenewswire.com · 14 Sep 2026

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across human and canine osteosarcoma models.

defenseworld.net · 12 Aug 2026

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?

Shares of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO - Get Free Report) were down 3.4% during mid-day trading on Tuesday. The company traded as low as $1.13 and last traded at $1.13. 27,578 shares traded hands during trading, a decline of 74% from the average daily volume of 104,128 shares. The stock had previously closed at

accessnewswire.com · 15 Jun 2026

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism Across Multiple Disease Models. MIAMI, FL / ACCESS Newswire / June 15, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity and significant improvement in glucose homeostasis with Telomir-Zn in a diet-induced zebrafish model of Type 2 diabetes mellitus (T2DM).